Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties

Cancer Immunology, Immunotherapy

Volumn 62, Issue 4, 2013, Pages 811-822

  Ott, Patrick A ^a   Henry, Trevor ^a   Baranda, Sonja Jimenez ^a   Frleta, Davor ^a   Manches, Olivier ^a   Bogunovic, Dusan ^a   Bhardwaj, Nina ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRAF; Dendritic cell; Immune suppression; MEK; Melanoma; Tumor microenvironment

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; B RAF KINASE; B7 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CYTOKINE; GLUTAMIC ACID; INTERLEUKIN 12; MITOGEN ACTIVATED PROTEIN KINASE; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3; TUMOR NECROSIS FACTOR ALPHA; VALINE; VEMURAFENIB;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL MATURATION; CELL MUTANT; CELL VIABILITY; COCULTURE; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LYMPHOCYTE FUNCTION; MELANOMA CELL; MONOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANTIGENS, CD; ANTIGENS, CD40; ANTIGENS, CD80; BUTADIENES; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNOGLOBULINS; INDOLES; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; MELANOMA; MEMBRANE GLYCOPROTEINS; MUTATION; NITRILES; POLY I-C; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; T-LYMPHOCYTES;

EID: 84877817680     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1389-z     Document Type: Article

References (45)

1. Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516. doi: 10.1056/NEJMoa1103782
2. Flaherty KT, Puzanov I, Kim KB et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819. doi: 10.1056/NEJMoa1002011
3. Sosman JA, Kim KB, Schuchter L et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-714. doi: 10.1056/NEJMoa1112302
4. Flaherty KT, Infante JR, Daud A et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. doi: 10.1056/NEJMoa1210093
5. Flaherty KT, Robert C, Hersey P et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. doi: 10.1056/NEJMoa1203421
6. Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723. doi: 10.1056/NEJMoa1003466
7. Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526. doi: 10.1056/NEJMoa1104621
8. Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465. doi: 10.1056/NEJMoa1200694
9. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454. doi: 10.1056/NEJMoa1200690
10. Dudley ME, Yang JC, Sherry R et al (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26:5233-5239. doi: 10.1200/JCO.2008.16.5449
11. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263-274. doi: 10.1038/nrc1586
12. Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295-307
13. Yang Z-Z, Novak AJ, Stenson MJ, Witzig TE, Ansell SM (2006) Intratumoral CD4+ CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 107:3639-3646
14. Viguier M, Lemaitre F, Verola O, Cho M-S, Gorochov G, Dubertret L, Bachelez H, Kourilsky P, Ferradini L (2004) Foxp3 expressing CD4+ CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol (Baltimore, Md: 1950) 173:1444-1453
15. Dong H, Chen L (2003) B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med 81:281-287
16. Freeman GJ, Long AJ, Iwai Y et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027-1034
17. Wang T, Niu G, Kortylewski M et al (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10:48-54
18. Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7:41-51
19. Boni A, Cogdill AP, Dang P et al (2010) Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70:5213-5219. doi: 10.1158/0008-5472.CAN-10-0118
20. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, Kefford RF, Hersey P, Scolyer RA (2012) Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 18:1386-1394. doi: 10.1158/1078-0432.CCR-11-2479
21. Adams S, O'Neill DW, Bhardwaj N (2005) Recent advances in dendritic cell biology. J Clin Immunol 25:177-188
22. Lee AW, Truong T, Bickham K, Fonteneau JF, Larsson M, Da Silva I, Somersan S, Thomas EK, Bhardwaj N (2002) A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 20(Suppl 4):A8-A22
23. Gorden A, Osman I, Gai W, He D, Huang W, Davidson A, Houghton AN, Busam K, Polsky D (2003) Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 63:3955-3957
24. Sondergaard JN, Nazarian R, Wang Q et al (2010) Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific RAF inhibitor PLX4032. J Transl Med 8:39. doi: 10.1186/1479-5876-8-39
25. Smalley KS, Contractor R, Haass NK, Lee JT, Nathanson KL, Medina CA, Flaherty KT, Herlyn M (2007) Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. Br J Cancer 96:445-449. doi: 10.1038/sj.bjc.6603596
26. Callahan M (2011) Defining the effects of MAPK pathway inhibition in human immune cells. Perspectives in Melanoma XV. Imedex, New York, NY
27. Comin-Anduix B, Chodon T, Sazegar H et al (2010) The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res 16:6040-6048. doi: 10.1158/1078-0432.CCR-10-1911
28. Flaherty KT, Robert C, Hersey P et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107-114. doi: 10.1056/NEJMoa1203421
29. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y (2006) The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 203:1651-1656. doi: 10.1084/jem.20051848
30. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma R, Thompson JF, Kefford RF, Hersey P, Scolyer RA (2011) Selective BRAF inhibitors induce marked T cell infiltration into human metastatic melanoma. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-11-2479
31. Vujanovic L, Ballard W, Thorne SH, Vujanovic NL, Butterfield LH (2012) Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10. Oncoimmunology 1:448-457
32. Jackson AM, Mulcahy LA, Zhu XW, O'Donnell D, Patel PM (2008) Tumour-mediated disruption of dendritic cell function: inhibiting the MEK1/2-p44/42 axis restores IL-12 production and Th1-generation. Int J Cancer 123:623-632. doi: 10.1002/ijc.23530
33. Bogunovic D, Manches O, Godefroy E, Yewdall A, Gallois A, Salazar AM, Marie I, Levy DE, Bhardwaj N (2011) TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity. Cancer Res 71:5467-5476. doi: 10.1158/0008-5472.CAN-10- 3988
34. Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA (2010) Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in BRAF-mutant human cutaneous melanoma cells. Cancer Res 70:8736-8747. doi: 10.1158/0008-5472.CAN-10-0902
35. VanBrocklin MW, Verhaegen M, Soengas MS, Holmen SL (2009) Mitogen-activated protein kinase inhibition induces translocation of BMF to promote apoptosis in melanoma. Cancer Res 69:1985-1994. doi: 10.1158/0008-5472.CAN-08-3934
36. Hong DS, Vence LM, Falchook GS et al (2012) Braf(V600) inhibitor Gsk2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-11-2515
37. Puig-Kroger A, Relloso M, Fernandez-Capetillo O, Zubiaga A, Silva A, Bernabeu C, Corbi AL (2001) Extracellular signal-regulated protein kinase signaling pathway negatively regulates the phenotypic and functional maturation of monocyte-derived human dendritic cells. Blood 98:2175-2182
38. Escors D, Lopes L, Lin R, Hiscott J, Akira S, Davis RJ, Collins MK (2008) Targeting dendritic cell signaling to regulate the response to immunization. Blood 111:3050-3061. doi: 10.1182/blood-2007-11-122408
39. Ardeshna KM, Pizzey AR, Devereux S, Khwaja A (2000) The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. Blood 96:1039-1046
40. Arrighi JF, Rebsamen M, Rousset F, Kindler V, Hauser C (2001) A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers. J Immunol 166:3837-3845
41. Martinez D, Vermeulen M, von Euw E et al (2007) Extracellular acidosis triggers the maturation of human dendritic cells and the production of IL-12. J Immunol 179:1950-1959
42. Yu Q, Kovacs C, Yue FY, Ostrowski MA (2004) The role of the p38 mitogen-activated protein kinase, extracellular signal-regulated kinase, and phosphoinositide-3-OH kinase signal transduction pathways in CD40 ligand-induced dendritic cell activation and expansion of virus-specific CD8+ T cell memory responses. J Immunol 172:6047-6056
43. Oberholzer PA, Kee D, Dziunycz P et al (2012) RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 30:316-321. doi: 10.1200/JCO.2011.36. 7680
44. Su F, Viros A, Milagre C et al (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366:207-215. doi: 10.1056/NEJMoa1105358
45. Hong DS, Vence L, Falchook G et al (2012) BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res 18:2326-2335. doi: 10.1158/1078-0432.CCR-11- 2515